{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:14Z","timestamp":1790188154754,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":158,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Tehran University of Medical Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Biomed. Mater. Res."],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1002\/jbm.a.35446","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T06:13:13Z","timestamp":1426313593000},"page":"3148-3156","source":"Crossref","is-referenced-by-count":109,"title":["Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment"],"prefix":"10.1002","volume":"103","author":[{"given":"Reyhaneh","family":"Varshochian","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy; Tehran University of Medical Sciences; Tehran Iran"},{"name":"Nanotechnology Research Centre, Faculty of Pharmacy; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Riazi-Esfahani","sequence":"additional","affiliation":[{"name":"Farabi Eye Hospital; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Jeddi-Tehrani","sequence":"additional","affiliation":[{"name":"Monoclonal Antibody Research Center; Avicenna Research Institute, ACECR; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad-Reza","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Monoclonal Antibody Research Center; Avicenna Research Institute, ACECR; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Aghazadeh","sequence":"additional","affiliation":[{"name":"Stem Cells Preparation Unit, Eye Research Center; Farabi Eye Hospital; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirgholamreza","family":"Mahbod","sequence":"additional","affiliation":[{"name":"Noor Eye Hospital; Noor Ophthalmology Research Center; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Movassat","sequence":"additional","affiliation":[{"name":"Farabi Eye Hospital; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Atyabi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy; Tehran University of Medical Sciences; Tehran Iran"},{"name":"Nanotechnology Research Centre, Faculty of Pharmacy; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Sabzevari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rassoul","family":"Dinarvand","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy; Tehran University of Medical Sciences; Tehran Iran"},{"name":"Nanotechnology Research Centre, Faculty of Pharmacy; Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"10.1002\/jbm.a.35446-BIB0001|jbma35446-cit-0002","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ajo.2011.08.011","article-title":"Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: Clinical andeconomic impact","volume":"153","author":"Shienbaum","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/jbm.a.35446-BIB0002|jbma35446-cit-0003","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajo.2012.06.007","article-title":"Short-term topical bevacizumab in the treatment of stable corneal neovascularization","volume":"154","author":"Cheng","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/jbm.a.35446-BIB0003|jbma35446-cit-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2008.10.001","article-title":"Molecular pathology of age-related macular degeneration","volume":"28","author":"Dinga","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1002\/jbm.a.35446-BIB0004|jbma35446-cit-0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.survophthal.2006.10.017","article-title":"Ocular neovascularization: Basic mechanisms and therapeutic advances","volume":"52(Suppl1)","author":"Dorrell","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"10.1002\/jbm.a.35446-BIB0005|jbma35446-cit-0006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jcjo.2011.12.009","article-title":"Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary tomyopia: 4-year study results","volume":"47","author":"Peiretti","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"10.1002\/jbm.a.35446-BIB0006|jbma35446-cit-0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ophtha.2011.08.032","article-title":"Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis","volume":"119","author":"Cionni","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/jbm.a.35446-BIB0007|jbma35446-cit-0008","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor-a in patients with choroidal neovascularization","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1002\/jbm.a.35446-BIB0008|jbma35446-cit-0009","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1444-0938.2008.00305.x","article-title":"Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: A review of current practice","volume":"91","author":"Wijngaarden","year":"2008","journal-title":"Clin Exp Optom"},{"key":"10.1002\/jbm.a.35446-BIB0009|jbma35446-cit-0010","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3109\/03639045.2012.736515","article-title":"Recent advances in ocular drug delivery","volume":"39","author":"Achouri","year":"2013","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jbm.a.35446-BIB0010|jbma35446-cit-0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nano.2011.05.016","article-title":"Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging","volume":"8","author":"Parveen","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1002\/jbm.a.35446-BIB0011|jbma35446-cit-0012","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1002\/jbm.a.35446-BIB0012|jbma35446-cit-0013","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.nano.2010.02.002","article-title":"In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems","volume":"6","author":"Semete","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1002\/jbm.a.35446-BIB0013|jbma35446-cit-0014","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: An overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"10.1002\/jbm.a.35446-BIB0014|jbma35446-cit-0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejpb.2004.10.006","article-title":"Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles","volume":"59","author":"Bilati","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jbm.a.35446-BIB0015|jbma35446-cit-0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2011.06.008","article-title":"Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer","volume":"416","author":"He","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1002\/jbm.a.35446-BIB0016|jbma35446-cit-0017","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1023\/A:1026498209874","article-title":"Protein instability in poly(lactic-co-glycolic acid) microparticles","volume":"17","author":"Weert","year":"2000","journal-title":"Pharm Res"},{"key":"10.1002\/jbm.a.35446-BIB0017|jbma35446-cit-0018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","article-title":"The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments","volume":"50","author":"Varshochian","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jbm.a.35446-BIB0018|jbma35446-cit-0019","first-page":"525","article-title":"Human serum albumin nanoparticles as an efficiennoscapine drug delivery system for potential use in breast cancer: Preparation and in vitro analysis","volume":"5","author":"Sebak","year":"2010","journal-title":"Int J Nanomed"},{"key":"10.1002\/jbm.a.35446-BIB0019|jbma35446-cit-0020","first-page":"170","volume-title":"Applied Biopharmaceutics and Pharmacokinetics","author":"Shargel","year":"2005","edition":"5"},{"key":"10.1002\/jbm.a.35446-BIB0020|jbma35446-cit-0021","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jop.2010.0158","article-title":"Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model","volume":"27","author":"Pan","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1002\/jbm.a.35446-BIB0021|jbma35446-cit-0022","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol J"},{"key":"10.1002\/jbm.a.35446-BIB0022|jbma35446-cit-0023","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration","volume":"29","author":"Abrishami","year":"2009","journal-title":"Retina"},{"key":"10.1002\/jbm.a.35446-BIB0023|jbma35446-cit-0024","first-page":"1","article-title":"Effect ofintravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats","volume":"7","author":"Lu","year":"2014","journal-title":"Int J Ophtalmol"},{"key":"10.1002\/jbm.a.35446-BIB0024|jbma35446-cit-0025","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1002\/adfm.201000907","article-title":"Sustained release of a monoclonal antibody from electrochemically prepared mesoporous silicon oxide","volume":"20","author":"Andrew","year":"2010","journal-title":"Adv Funct Mater"},{"key":"10.1002\/jbm.a.35446-BIB0025|jbma35446-cit-0026","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijbiomac.2013.05.034","article-title":"Sustained release of Avastin\u00ae from polysaccharides crosslinked hydrogels for ocular drug delivery","volume":"60","author":"Xu","year":"2013","journal-title":"Int J Biol Macromol"},{"key":"10.1002\/jbm.a.35446-BIB0026|jbma35446-cit-0027","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bm2009558","article-title":"Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel","volume":"13","author":"Wang","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1002\/jbm.a.35446-BIB0027|jbma35446-cit-0028","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1167\/iovs.13-13120","article-title":"Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo","volume":"55","author":"Rauck","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1002\/jbm.a.35446-BIB0028|jbma35446-cit-0029","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1002\/jbm.a.35446-BIB0029|jbma35446-cit-0030","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1002\/jbm.a.35446-BIB0030|jbma35446-cit-0031","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/jbm.a.35446-BIB0031|jbma35446-cit-0032","doi-asserted-by":"crossref","unstructured":"El Sanharawi M Kowalczuk L Touchard E Omri S de Kozak Y Behar-Cohen F. Protein delivery for retinal diseases: From basic considerations to clinical applications Prog Retin Eye Res 2010 29 443 465","DOI":"10.1016\/j.preteyeres.2010.04.001"},{"key":"10.1002\/jbm.a.35446-BIB0032|jbma35446-cit-0033","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013007419","article-title":"A pharmacokinetic overview of nanotechnology-based drug delivery systems: An ADME-oriented approach","volume":"30","author":"Hamidi","year":"2013","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1002\/jbm.a.35446-BIB0033|jbma35446-cit-0034","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1002\/jbm.a.35446-BIB0034|jbma35446-cit-0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2008.12.007","article-title":"Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor","volume":"371","author":"Yang","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1002\/jbm.a.35446-BIB0035|jbma35446-cit-0036","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.colsurfb.2012.04.002","article-title":"Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis","volume":"97","author":"Tomoda","year":"2012","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1002\/jbm.a.35446-BIB0036|jbma35446-cit-0037","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.colsurfb.2012.12.027","article-title":"Distribution and deposition of respirable PLGA microspheres in lung alveoli","volume":"105","author":"Hirota","year":"2013","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1002\/jbm.a.35446-BIB0037|jbma35446-cit-0038","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","article-title":"Drug delivery systems for vitreoretinal diseases","volume":"23","author":"Yasukawa","year":"2004","journal-title":"Prog Retin Eye Res"},{"key":"10.1002\/jbm.a.35446-BIB0038|jbma35446-cit-0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000055638","article-title":"Effect of particle size of polymeric nanospheres on intravitreal kinetics","volume":"33","author":"Sakurai","year":"2001","journal-title":"Ophthalmic Res"}],"container-title":["Journal of Biomedical Materials Research Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbm.a.35446","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jbm.a.35446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T14:00:32Z","timestamp":1625493632000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jbm.a.35446"}},"subtitle":["ALBUMINATED PLGA NANOPARTICLES FOR OCULAR NEOVASCULARIZATION TREATMENT"],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/jbm.a.35446","archive":["Portico"],"relation":{},"ISSN":["1549-3296"],"issn-type":[{"value":"1549-3296","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}